Small Molecule Enhancers of Oncolytic Immunotherapy Jean-Simon Diallo1,2 et al. 1Ottawa Hospital Research Institute, Cancer Therapeutics Program; 2University of Ottawa, Department of Biochemistry, Microbiology, and Immunology
Oncolytic viruses comprise a new set of clinical tools in the fight against cancer. However, these immunotherapeutic agents hit a roadblock in the context of heterogenous tumors that can mount an effective antiviral response. We have discovered using high-throughput screening and/or rational approaches, a variety of small molecules that enhance the activity of oncolytic viruses in cancer cells. These novel small molecules termed "viral sensitizers" work in a variety of ways to deter the immune response away from the virus, allowing for vastly improved infection. Here we will present recent data highlighting the capacity of vanadium-based compounds to shift type I antiviral responses towards a type II pro-inflammatory phenotype that favours adaptive anti-tumor effects. We will also present our recent findings regarding the effectiveness of targeting NF-B nuclear translocation using both novel and approved drugs as in combination with oncolytic viruses in vitro and in vivo.
Funding sources: Terry Fox Research Institute, Canadian Cancer Society Research Institute, Canadian Institutes of Health Research (CIHR), National Sciences and Engineering Research Council (NSERC)
Credits: None available.
You must be logged in and own this product in order to